S453
Clinical - Gynaecological
ESTRO 2026
frequency: every 3–6 months the first two years (>80%) and every 6–12 months thereafter (>75%). FU adaptation according to patient or disease characteristics was frequent: in 61% for OC patients receiving maintenance therapy, in 52% for CC based on HPV risk status, and in 76% EC according to recurrence risk, of which 87% indicated molecular profiling guided decisions. Conclusion: Marked heterogeneity exists in GM surveillance practices, despite international guidelines. As molecular profiling and risk- adapted management increasingly shape patient care, FU will become more complex. Clear, evidence-based, and harmonised FU strategies are essential to ensure consistent, personalised, and cost-effective surveillance. For radiation oncologists, central to post- treatment monitoring and recurrence detection, standardised and multidisciplinary FU protocols are particularly crucial to optimise long-term outcomes and resource allocation. References: Concin N, Matias-Guiu X, Cibula D, et al. ESGO-ESTRO-ESP guidelines for the management of patients with endometrial carcinoma: update 2025. Lancet Oncol. 2025 Aug;26(8):e423-e435. doi: 10.1016/S1470- 2045(25)00167-6. Erratum in: Lancet Oncol. 2025 Oct;26(10):e522. doi: 10.1016/S1470- 2045(25)00560-1. PMID: 40744042.Cibula D,
Digital Poster 2549
Association between bone marrow dose– SUV distribution and hematologic toxicity in pelvic chemoradiotherapy for cervical cancer Fumiaki Isohashi 1 , Nobuyoshi Inooka 1 , Nobuhide Wakai 1 , Sachiko Miura 1 , Yuichi Akino 2 1 Department of Radiation Oncology, Nara Medical University, Kashihara, Japan. 2 Department of Radiation Oncology, The university of Osaka, Suita, Japan Purpose/Objective: To investigate the relationship between hematologic toxicity (HT) and dose/SUV distributions in pelvic bones during concurrent chemoradiotherapy (CCRT) with weekly cisplatin for cervical cancer. Material/Methods: Between April 2020 and May 2025, 36 patients with cervical cancer who underwent pelvic CCRT and had pre-treatment diagnostic PET-CT were retrospectively analyzed. PET-CT and planning CT images were co-registered using deformable image registration to evaluate voxel-wise correspondence between SUV and dose. Bone regions were delineated as follows: the lumbar spine (below the superior border of L2), the upper and lower pelvic bones (divided at the level of the superior border of the femoral head), the sacrum, and the femur (from the lesser trochanter to 3 cm below) (Figure). For each region, the proportions of voxels receiving ≥ 10, ≥ 20, ≥ 30, and ≥ 40 Gy (V10-40Gy) and those with SUV ≥ 1.0 were calculated. HT was defined as grade ≥ 3 leukopenia or neutropenia according to CTCAE v5.0.
Raspollini MR, Planchamp F, et al. ESGO/ESTRO/ESP Guidelines for the
management of patients with cervical cancer - Update 2023. Int J Gynecol Cancer. 2023 May 1;33(5):649-666. doi: 10.1136/ijgc-2023- 004429. PMID: 37127326; PMCID: PMC10176411.https://www.esgo.org/media/2 025/08/Pocket-Guidelines_Ovarian-cancer- consensus.pdf Keywords: Gynaecological tumor; Follow-up; Practice patterns
Made with FlippingBook - Share PDF online